Intermediate Markers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.

University of georgiaUnited statesMarkh ebellUniversity of georgia markh ebellFood drug administrationClinical benefitFinancial costsIntermediate markersDrug administrationDisease assessment scaleMini mental state examinationClinical dementia rating sumDisease assessmentAlzheimer diseaseAlzheimer x27 sAlzheimer x27s disease